January 28, 2025

Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund

Clarametyx Biosciences Announces Investment by
Kineticos AMR Accelerator Fund

COLUMBUS, Ohio – January 28, 2025 – Clarametyx Biosciences Inc. (“Clarametyx”), a clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, and Kineticos Life Sciences (“Kineticos”), a life sciences investor focused on companies striving to disrupt how drugs are developed, diseases are diagnosed, and patients are treated, today announced an investment by the Kineticos AMR Accelerator Fund I, L.P. (“KAMRA Fund”). Aligned with the investment, KAMRA Venture Partner Douglas Thomson will join the Clarametyx Board of Directors.

This investment extends the Company’s Series A funding completed in 2024 to drive momentum across the Clarametyx pipeline, including the ongoing CMTX-101 trial in cystic fibrosis-related infections in collaboration with the Cystic Fibrosis Foundation, and development of the CMTX-301 vaccine against recurrent bacterial infections, which was recently funded by CARB-X.

“We graciously welcome the KAMRA Fund as an investor and advisor to Clarametyx. As a dedicated champion for innovation and operational excellence, the KAMRA team brings a like-minded sense of urgency and purpose to our mission, and we are confident they will propel our efforts as we work to address critical unmet needs in chronic respiratory disease,” said David Richards, Chief Executive Officer, Clarametyx.

“The Clarametyx scientific strategy is well aligned to our core focus on technologies and solutions to address antimicrobial resistance. We are eager to partner with the Clarametyx team to accelerate development and bring forward a potentially transformative platform strategy for this urgent global challenge,” said Douglas Thomson, Venture Partner at the KAMRA Fund.

About Clarametyx Biosciences

Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines for serious bacterial infections associated with biofilms, with a near-term focus on chronic respiratory diseases. For more information, visit us on the web or on LinkedIn.

About Kineticos Life Sciences

Kineticos envisions A World Without AMR, cancer and rare diseasesTM. We are entrepreneurs helping entrepreneurs build companies to improve patient outcomes. Kineticos invests in life science companies focused on significant, unmet medical needs across contract services, manufacturing, equipment, and therapeutic companies. Kineticos strives to disrupt how drugs are developed, diseases are diagnosed, and patients are treated.

Clarametyx Media Contact:

Kellie Hotz
khotz@clarametyx.com

Kineticos Media Contact:

investorrelations@kineticos.com

# # #

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.